1 – 12 of 12
- show: 100
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2020
-
Mark
The prospective Hemophilia Inhibitor PUP Study reveals distinct antibody signatures prior to FVIII inhibitor development
(
- Contribution to journal › Article
- 2014
-
Mark
A comparison of the treatment of patients with factor IX deficiency to that of those with factor VIII deficiency: results of an International Survey conducted as part of the International FIX Treatment Network.
(
- Contribution to journal › Letter
- 2013
-
Mark
F8 haplotype and inhibitor risk: results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort
(
- Contribution to journal › Article
- 2012
-
Mark
The international factor IX treatment network survey.
(
- Contribution to journal › Letter
- 2010
-
Mark
The international factor IX treatment network survey
2010) 3rd Annual Congress of the European Association for Haemophilia and Allied Disorders In Haemophilia 16(2). p.403-403(
- Contribution to journal › Published meeting abstract
- 2008
-
Mark
Secondary prophylaxis with recombinant activated factor VII improves health-related quality of life of haemophilia patients with inhibitors
(
- Contribution to journal › Article
- 2006
-
Mark
Inhibitor treatment in haemophilas A and B: Summary statement for the 2006 International Consensus Conference
(
- Contribution to journal › Debate/Note/Editorial
- 2005
-
Mark
Haemophilia Inhibitor Genetics Study - evaluation of a model for studies of complex diseases using linkage and association methods.
(
- Contribution to journal › Letter
- 2003
-
Mark
Impact of inhibitor epitope profile on the neutralizing effect against plasma-derived and recombinant factor VIII concentrates in vitro.
(
- Contribution to journal › Article
-
Mark
Consensus perspectives on prophylactic therapy for haemophilia: summary statement.
(
- Contribution to journal › Letter
- 2001
-
Mark
Pharmacokinetics of recombinant factor IX in relation to age of the patient: implications for dosing in prophylaxis
(
- Contribution to journal › Article
- 2000
-
Mark
The optimal treatment for haemophiliacs who have developed factor VIII or -IX antibodies
(
- Contribution to journal › Article